Portal de Periódicos da CAPES

Pilot Trial AMC-063: Safety and Efficacy of Bortezomib in AIDS-associated Kaposi Sarcoma

2019; American Association for Cancer Research; Volume: 26; Issue: 3 Linguagem: Inglês

10.1158/1078-0432.ccr-19-1044

1557-3265

Erin Reid, Adrienne Suazo, Shelly Lensing, Dirk P. Dittmer, Richard F. Ambinder, Frank Maldarelli, Robert J. Gorelick, David M. Aboulafia, Ronald T. Mitsuyasu, Mark A. Dickson, William Wachsman,

Lymphoma Diagnosis and Treatment

AIDS-related Kaposi sarcoma is often incompletely controlled, requiring serial therapies. Kaposi sarcoma herpesvirus (KSHV) induces transformation of endothelial cells, where it resides in a predominately latent state. We hypothesized proteasome inhibition would have direct antitumor activity, induce lytic activation of KSHV, and inhibit HIV infectivity, improving control of both Kaposi sarcoma and HIV. The primary objective was determining the MTD of bortezomib in AIDS-Kaposi sarcoma. Secondary objectives included estimating the impact of bortezomib on Kaposi sarcoma response, KSHV plasma DNA copy number (PDCN), and HIV viral loads (VL).